The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

NCT ID: NCT04252495

Last Updated: 2022-11-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-26
• Study Completion Date: 2021-05-06

Brief Summary

This is a prospective, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).

Conditions

Hepatic Impairment; Healthy Subjects

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Subjects with moderate hepatic impairment (Group 1)

Group Type: EXPERIMENTAL

Aprocitentan

Intervention Type: DRUG

A single oral dose of 25 mg.

Healthy subjects (Group 2)

Group Type: EXPERIMENTAL

Aprocitentan

Intervention Type: DRUG

A single oral dose of 25 mg.

Interventions

Aprocitentan

A single oral dose of 25 mg.

Intervention Type: DRUG

Other Intervention Names

ACT-132577

Eligibility Criteria

Inclusion Criteria

• Signed informed consent in a language understandable to the subject prior to any study-mandated procedure.
• Women of childbearing potential (WoCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1 and must agree to use highly effective methods of contraception from screening up to 30 days after study treatment.
• A Women of non-childbearing potential (WoNCBP) must meet one of the following criteria:

• Previous bilateral salpingectomy, salpingo-oophorectomy or hysterectomy.
• Premature ovarian failure confirmed by a specialist gynecologist.
• Post-menopausal, defined as 12 consecutive months with amenorrhea prior to screening without alternative medical cause and confirmed with a follicle stimulating hormone test.
• Body mass index of 18.0 to 35.0 kg/m2 (inclusive) at screening.
• Normal renal function confirmed by a creatinine clearance at screening according to Cockcroft and Gault adjusted to age.

• Moderate hepatic function impairment due to liver cirrhosis defined as a score of 7-9 (inclusive) according to the Child-Pugh classification.
• Systolic blood pressure 95 to 160 mmHg, diastolic blood pressure 60 to 95 mmHg, and pulse rate 50 to 100 bpm (inclusive), measured on the same arm, after 5 minutes in the supine position at screening and on Day 1 pre-dose.
• International normalized ratio equal or less than 2.5 at screening.
• Stable concomitant medications for at least 3 weeks prior to screening and up to Day 1 and expected to be stable during the conduct of the study.

• Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests.

Exclusion Criteria

• Pregnant or lactating women.
• Previous exposure to aprocitentan and/or macitentan.
• Known hypersensitivity to any excipients of the drug formulation.
• Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
• Any signs or symptoms of active, ongoing infection judged to be clinically relevant by the investigator (special attention should be given to COVID-19, e.g., fever, dry cough, dyspnea, sore throat, or fatigue).
• Subjects must adhere to the clinical site's house rules, which include, amongst others, polymerase chain reaction testing for SARS-CoV-2 at screening and admission.
• Legal incapacity or limited legal capacity at screening.

• History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion (ADME) of the study treatment except for those related to liver cirrhosis (appendectomy and herniotomy allowed, cholecystectomy not allowed).
• Hepatic cancer, primary biliary cirrhosis, or any form of cholestatic disease.
• Clinical evidence or suspected acute liver failure as judged by the investigator.
• Encephalopathy grade greater than 2.
• Severe ascites and/or pleural effusion.
• Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at screening & on Day -1, except for those related to liver cirrhosis.

• Clinically relevant findings on the physical examination at screening.
• History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion (ADME) of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).
• Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at screening & on Day -1.
• Clinically relevant abnormalities on a 12-lead ECG, recorded after 5 min in the supine position at screening & on Day 1 pre-dose.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Idorsia Pharmaceuticals Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Idorsia Pharmaceuticals Ltd.

Locations

CRS Clinical Research Services Kiel GmbH

Kiel, , Germany

Biokinetica S.A.

Józefów, , Poland

Countries

Germany; Poland

References

Fontes MSC, Dingemanse J, Halabi A, Tomaszewska-Kiecana M, Sidharta PN. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. Sci Rep. 2022 Nov 9;12(1):19067. doi: 10.1038/s41598-022-22470-z.

Reference Type: DERIVED

PMID: 36352054 (View on PubMed)

Other Identifiers

2019-003580-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ID-080-109

Identifier Type: -

Identifier Source: org_study_id